argenx posts ADAPT SERON Phase 3 results; registers new Phase 2 in Sjögren's neuropathy

argenx had two notable trial updates this week, one with results posted and one newly registered.

• ADAPT SERON (NCT06298552), a Phase 3 trial of efgartigimod IV in adults with acetylcholine receptor binding antibody seronegative generalized myasthenia gravis, posted results on 2026-08-10. The study enrolled 119 participants¹ and measured MG-ADL Total Score Change From Baseline, an 8-item scale assessing myasthenia gravis symptoms and their effects on daily activities, ranging from 0 to 24, up to 29 days in part A¹.
• SERENITY (NCT07760818), a Phase 2 trial titled "A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants With Sjogren's Disease-Associated Sensorimotor or Sensory Polyneuropathy," was first posted on 2026-08-12 and is not yet recruiting. The trial plans to enroll 75 participants (estimated)² and will assess change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A, a clinician-reported measure with a total possible range of 0 to 33, where higher scores indicate greater neuropathy severity².